Why the study?
This critical review aimed to elucidate the possible protective role of montelukast in the management of ACS.
Does montelukast reduce the severity of acute coronary syndrome and associated complications in patients with ACS?
Does montelukast reduce the severity of acute coronary syndrome and associated complications in patients with ACS?
This review proposes that montelukast may have a protective role in acute coronary syndrome by inhibiting leukotriene-mediated inflammation and thrombosis, warranting future clinical investigation.
No takes yet. Share an insight, caveat, or question.
LT pathway activation may promote immunothrombosis in ACS; leaves open CysLT-targeted therapies for prospective trials.
Alomair et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: